Menadex (Dexketoprofen)

Dexketoprofen inhibits the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, reducing the synthesis of prostaglandins that mediate inflammation, fever, and pain. By lowering prostaglandin levels, it diminishes peripheral nociceptor sensitisation and decreases inflammatory swelling, producing analgesic, anti‑inflammatory and antipyretic effects.

The exact dose of Menadex is determined by the prescribing clinician based on the severity of pain, the patient’s weight, renal and hepatic function, and the intended route of administration (intramuscular or intravenous). No fixed regimen is provided here; the prescriber sets the appropriate amount.

Safety data for dexketoprofen in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To place an order, submit an enquiry on the Menadex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Dexketoprofen is the S‑enantiomer of ketoprofen and offers a faster onset of analgesia compared with many oral NSAIDs, including ibuprofen. Its injectable form allows rapid plasma concentrations, making it useful for acute procedural pain, whereas ibuprofen is typically administered orally and has a slower peak effect.

Menadex should be stored in a refrigerator at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain to preserve stability.

Menadex is supplied as a sterile injectable solution and is administered by a qualified healthcare professional either intramuscularly or intravenously, depending on the clinical situation. The injection is given under aseptic conditions, and the dose is adjusted by the prescriber according to the patient’s needs.

Serious adverse events include gastrointestinal bleeding or ulcer perforation, acute renal impairment, severe hypersensitivity reactions such as anaphylaxis, hepatic dysfunction, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for signs of these complications, especially if they have pre‑existing risk factors.

Menadex should be avoided in individuals with known hypersensitivity to dexketoprofen or other NSAIDs, active gastrointestinal ulcer or bleeding, severe renal or hepatic impairment, uncontrolled hypertension, and in patients who have recently experienced a myocardial infarction or stroke unless specifically advised by a physician.